Literature DB >> 28025581

PML-RARA-associated cooperating mutations belong to a transcriptional network that is deregulated in myeloid leukemias.

C Ronchini1, A Brozzi2, L Riva1, L Luzi2, A M Gruszka2, G E M Melloni1, E Scanziani3,4, G Dharmalingam5, M Mutarelli5, V Belcastro6, S Lavorgna7,8, V Rossi9, O Spinelli10, A Biondi11, A Rambaldi10, F Lo-Coco7,8, D di Bernardo5, P G Pelicci2,12.   

Abstract

It has been shown that individual acute myeloid leukemia (AML) patients are characterized by one of few initiating DNA mutations and 5-10 cooperating mutations not yet defined among hundreds identified by massive sequencing of AML genomes. We report an in vivo insertional-mutagenesis screen for genes cooperating with one AML initiating mutations (PML-RARA, oncogene of acute promyelocytic leukemia, APL), which allowed identification of hundreds of genetic cooperators. The cooperators are mutated at low frequency in APL or AML patients but are always abnormally expressed in a cohort of 182 APLs and AMLs analyzed. These deregulations appear non-randomly distributed and present in all samples, regardless of their associated genomic mutations. Reverse-engineering approaches showed that these cooperators belong to a single transcriptional gene network, enriched in genes mutated in AMLs, where perturbation of single genes modifies expression of others. Their gene-ontology analysis showed enrichment of genes directly involved in cell proliferation control. Therefore, the pool of PML-RARA cooperating mutations appears large and heterogeneous, but functionally equivalent and deregulated in the majority of APLs and AMLs. Our data suggest that the high heterogeneity of DNA mutations in APLs and AMLs can be reduced to patterns of gene expression deregulation of a single 'mutated' gene network.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 28025581     DOI: 10.1038/leu.2016.386

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  49 in total

Review 1.  Retroviral insertional mutagenesis: past, present and future.

Authors:  A G Uren; J Kool; A Berns; M van Lohuizen
Journal:  Oncogene       Date:  2005-11-21       Impact factor: 9.867

2.  Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence.

Authors:  Giulio Genovese; Anna K Kähler; Robert E Handsaker; Johan Lindberg; Samuel A Rose; Samuel F Bakhoum; Kimberly Chambert; Eran Mick; Benjamin M Neale; Menachem Fromer; Shaun M Purcell; Oscar Svantesson; Mikael Landén; Martin Höglund; Sören Lehmann; Stacey B Gabriel; Jennifer L Moran; Eric S Lander; Patrick F Sullivan; Pamela Sklar; Henrik Grönberg; Christina M Hultman; Steven A McCarroll
Journal:  N Engl J Med       Date:  2014-11-26       Impact factor: 91.245

3.  Moloney murine leukemia virus infection accelerates lymphomagenesis in E mu-bcl-2 transgenic mice.

Authors:  Y Shinto; M Morimoto; M Katsumata; A Uchida; K Aozasa; M Okamoto; T Kurosawa; T Ochi; M I Greene; Y Tsujimoto
Journal:  Oncogene       Date:  1995-11-02       Impact factor: 9.867

Review 4.  Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet.

Authors:  Miguel A Sanz; David Grimwade; Martin S Tallman; Bob Lowenberg; Pierre Fenaux; Elihu H Estey; Tomoki Naoe; Eva Lengfelder; Thomas Büchner; Hartmut Döhner; Alan K Burnett; Francesco Lo-Coco
Journal:  Blood       Date:  2008-09-23       Impact factor: 22.113

5.  High-throughput retroviral tagging to identify components of specific signaling pathways in cancer.

Authors:  Harald Mikkers; John Allen; Puck Knipscheer; Like Romeijn; Augustinus Hart; Edwin Vink; Anton Berns; Lieke Romeyn
Journal:  Nat Genet       Date:  2002-08-19       Impact factor: 38.330

6.  New genes involved in cancer identified by retroviral tagging.

Authors:  Takeshi Suzuki; Haifa Shen; Keiko Akagi; Herbert C Morse; James D Malley; Daniel Q Naiman; Nancy A Jenkins; Neal G Copeland
Journal:  Nat Genet       Date:  2002-08-19       Impact factor: 38.330

7.  Effect of mutation order on myeloproliferative neoplasms.

Authors:  Christina A Ortmann; David G Kent; Jyoti Nangalia; Yvonne Silber; David C Wedge; Jacob Grinfeld; E Joanna Baxter; Charles E Massie; Elli Papaemmanuil; Suraj Menon; Anna L Godfrey; Danai Dimitropoulou; Paola Guglielmelli; Beatriz Bellosillo; Carles Besses; Konstanze Döhner; Claire N Harrison; George S Vassiliou; Alessandro Vannucchi; Peter J Campbell; Anthony R Green
Journal:  N Engl J Med       Date:  2015-02-12       Impact factor: 91.245

8.  Mutational landscape and significance across 12 major cancer types.

Authors:  Cyriac Kandoth; Michael D McLellan; Fabio Vandin; Kai Ye; Beifang Niu; Charles Lu; Mingchao Xie; Qunyuan Zhang; Joshua F McMichael; Matthew A Wyczalkowski; Mark D M Leiserson; Christopher A Miller; John S Welch; Matthew J Walter; Michael C Wendl; Timothy J Ley; Richard K Wilson; Benjamin J Raphael; Li Ding
Journal:  Nature       Date:  2013-10-17       Impact factor: 49.962

9.  The Mutational Landscape of Acute Promyelocytic Leukemia Reveals an Interacting Network of Co-Occurrences and Recurrent Mutations.

Authors:  Mariam Ibáñez; José Carbonell-Caballero; Luz García-Alonso; Esperanza Such; Jorge Jiménez-Almazán; Enrique Vidal; Eva Barragán; María López-Pavía; Marta LLop; Iván Martín; Inés Gómez-Seguí; Pau Montesinos; Miguel A Sanz; Joaquín Dopazo; José Cervera
Journal:  PLoS One       Date:  2016-02-17       Impact factor: 3.240

10.  Comprehensive mutational analysis of primary and relapse acute promyelocytic leukemia.

Authors:  V Madan; P Shyamsunder; L Han; A Mayakonda; Y Nagata; J Sundaresan; D Kanojia; K Yoshida; S Ganesan; N Hattori; N Fulton; K-T Tan; T Alpermann; M-C Kuo; S Rostami; J Matthews; M Sanada; L-Z Liu; Y Shiraishi; S Miyano; E Chendamarai; H-A Hou; G Malnassy; T Ma; M Garg; L-W Ding; Q-Y Sun; W Chien; T Ikezoe; M Lill; A Biondi; R A Larson; B L Powell; M Lübbert; W J Chng; H-F Tien; M Heuser; A Ganser; M Koren-Michowitz; S M Kornblau; H M Kantarjian; D Nowak; W-K Hofmann; H Yang; W Stock; A Ghavamzadeh; K Alimoghaddam; T Haferlach; S Ogawa; L-Y Shih; V Mathews; H P Koeffler
Journal:  Leukemia       Date:  2016-04-11       Impact factor: 11.528

View more
  6 in total

1.  FLT3-ITD impedes retinoic acid, but not arsenic, responses in murine acute promyelocytic leukemias.

Authors:  Cécile Esnault; Ramy Rahmé; Kim L Rice; Caroline Berthier; Coline Gaillard; Samuel Quentin; Anne-Lise Maubert; Scott Kogan; Hugues de Thé
Journal:  Blood       Date:  2019-01-23       Impact factor: 22.113

Review 2.  Differentiation therapy revisited.

Authors:  Hugues de Thé
Journal:  Nat Rev Cancer       Date:  2017-12-01       Impact factor: 60.716

3.  Dual origin of relapses in retinoic-acid resistant acute promyelocytic leukemia.

Authors:  Jacqueline Lehmann-Che; Cécile Bally; Eric Letouzé; Caroline Berthier; Hao Yuan; Florence Jollivet; Lionel Ades; Bruno Cassinat; Pierre Hirsch; Arnaud Pigneux; Marie-Joelle Mozziconacci; Scott Kogan; Pierre Fenaux; Hugues de Thé
Journal:  Nat Commun       Date:  2018-05-24       Impact factor: 14.919

4.  Pin1 inhibition exerts potent activity against acute myeloid leukemia through blocking multiple cancer-driving pathways.

Authors:  Xiaolan Lian; Yu-Min Lin; Shingo Kozono; Megan K Herbert; Xin Li; Xiaohong Yuan; Jiangrui Guo; Yafei Guo; Min Tang; Jia Lin; Yiping Huang; Bixin Wang; Chenxi Qiu; Cheng-Yu Tsai; Jane Xie; Ziang Jeff Gao; Yong Wu; Hekun Liu; Xiao Zhen Zhou; Kun Ping Lu; Yuanzhong Chen
Journal:  J Hematol Oncol       Date:  2018-05-30       Impact factor: 17.388

Review 5.  Acute Promyelocytic Leukemia: Update on the Mechanisms of Leukemogenesis, Resistance and on Innovative Treatment Strategies.

Authors:  N I Noguera; G Catalano; C Banella; M Divona; I Faraoni; T Ottone; W Arcese; M T Voso
Journal:  Cancers (Basel)       Date:  2019-10-18       Impact factor: 6.639

Review 6.  Acute Promyelocytic Leukemia: A Constellation of Molecular Events around a Single PML-RARA Fusion Gene.

Authors:  Alessandro Liquori; Mariam Ibañez; Claudia Sargas; Miguel Ángel Sanz; Eva Barragán; José Cervera
Journal:  Cancers (Basel)       Date:  2020-03-08       Impact factor: 6.639

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.